Table 1.
Formulation | Drug | Carrier | Type of Study | Main Target Tissue | In Vitro Model | In Vivo Model | Authors; Year; References |
---|---|---|---|---|---|---|---|
Microparticles | Doxycycline | PCL | Pre-clinical studies | Cartilage | 3D rabbit chondrocyte agarose model | Rabbits | Aydin et al. 2015 [44] |
Celecoxib | PEA | Pre-clinical studies | Synovium | Differentiated HI-60 cells and lysates | Human synovium and synovial fluid (ex vivo); rat ACLT model | Janssen et al. 2016 [32] |
|
Etoricoxib | PCL | Pre-clinical studies | Synovium, cartilage | Not reported | Rats | Arunkumar et al. 2016 [45] |
|
Lornoxicam | Chitosan/TPP | Pre-clinical studies | Synovium, cartilage | Not reported | Rat MIA model | Abd-Allah et al. 2016 [46] |
|
Fluvastatin | PLGA | Pre-clinical studies | Cartilage | Human primary chondrocytes | Rabbit ACLT model | Goto et al. 2017 [47] |
|
Rhein (cassic acid) | PLGA | Pre-clinical studies | Synovium | THP-1 macrophages | Not reported | Gomez-Gaete et al. 2017 [8] |
|
Kartogenin | PLA | Pre-clinical studies | Cartilage | Human synoviocytes | Mice DMM model | Maudens et al. 2018 [43] |
|
PH-797804, Dexamethasone | PLA | Pre-clinical studies | Synovium | Human synoviocytes | Mice AIA model | Maudens et al. 2018 [48] |
|
Triamcinolone acetonide (Zilretta™) | PLGA | Phase II/III clinical trials in OA patients 1 | Synovium, cartilage | Not reported | Rat knee model 2 | Kumar et al. 2015 2; Kraus et al. 2018 1 [49,50] |
|
TSG-6 (tumor necrosis factor-alpha stimulated gene-6) | Heparin | Pre-clinical studies | Cartilage | Not reported | Rat MMT model | Tellier et al. 2018 [39] |
|
Fluticasone propionate | PVA | Pre-clinical studies | Synovium | Not reported | Beagle dogs | Getgood et al. 2019 [51] |
|
Celecoxib | PLA | Pre-clinical studies | Synovium | Human synoviocytes | Not reported | Salgado et al. 2020 [52] |
|
Rapamycin | PLGA | Pre-clinical studies | Cartilage | Human immortal chondrocytes | Mice | Dhanabalan et al. 2020 [53] |
|
Nanoparticles | VX-745 (p38 MAPK inhibitor) | PLA and PLGA | Pre-clinical studies | Synovium | Human synoviocytes | Mice AIA model | Pradal et al. 2015 [40] |
Dexamethasone | Avidin/PEG | Pre-clinical studies | Synovium, cartilage | Bovine knee cartilage explants | Not reported | Bajpayee et al. 2016 [54] |
|
KAFAK (anti-inflammatory mitogen-activated protein kinase-activated protein kinase 2 (MK2)-inhibiting cell-penetrating peptide) | pNiPAM-PEG | Pre-clinical studies | Synovium, cartilage | Bovine knee cartilage explants | Not reported | Lin et al. 2016 [9] |
|
Kartogenin; Diclofenac | Chitosan/Pluronic F127 | Pre-clinical studies | Synovium, cartilage | Human BMSCs (bone marrow mesenchymal stem cells); Human primary chondrocytes | Rats | Kang et al. 2016 [35] |
|
Curcumin | PLGA | Pre-clinical studies | Synovium, cartilage | Not reported | Rats | Niazvand et al. 2017 [55] |
|
Dexamethasone | Avidin | Pre-clinical studies | Synovium | Not reported | Rabbit ACLT model | Bajpayee et al. 2017 [56] |
|
KAFAK | pNiPAM-PEG | Pre-clinical studies | Synovium, cartilage | RAW 264.7 macrophages; Bovine knee cartilage explants | Not reported | McMasters et al. 2017 [57] |
|
CAP (chondrocyte affinity peptide) | PEG-PAMAM | Pre-clinical studies | Cartilage | Human primary chondrocytes | Rats | Hu et al. 2018 [58] |
|
Kartogenin | Polyurethane | Pre-clinical studies | Cartilage | Rat primary chondrocytes | Rat ACLT model | Fan et al. 2018 [59] |
|
Adenosine | PEG-b-PLA | Pre-clinical studies | Synovium, cartilage | RAW 264.7 macrophages | Rat ACLT model | Liu et al. 2019 [60] |
|
Etoricoxib | PLGA-PEG-PLGA | Pre-clinical studies | Synovium, cartilage | Human primary chondrocytes | Rat ACLT model | Liu et al. 2019 [33] |
|
Hyaluronic acid | PLGA | Pre-clinical studies | Cartilage | RAW 264.7 macrophages | Brine shrimp; Rats | Mota et al. 2019 [61] |
|
Hyaluronic acid and near-infrared dye | PLGA | Pre-clinical studies | Cartilage | Human primary chondrocytes | Mice DMM model | Zerrillo et al. 2019 [62] |
|
Celastrol | Mesoporous silica | Pre-clinical studies | Cartilage | Rat primary chondrocytes | Rat MIA model | Jin et al. 2020 [63] |
|
Diacerein | PLGA | Pre-clinical studies | Synovium, cartilage | Rat synoviocytes | Rat MIA model | Jung et al. 2020 [64] |
|
Etoricoxib | PLA/Chitosan | Pre-clinical studies | Synovium | MC3T3-E1 cells (mouse osteoblast precursor) | Not reported | Salama et al. 2020 [65] |
|
MK2i (anti-inflammatory MK2-inhibiting peptide) | Linked and non-linked NIPAm | Pre-clinical studies | Synovium, cartilage | Bovine primary chondrocytes | Rats | Deloney et al. 2020 [66] |
|
Oxaceprol | PLGA | Pre-clinical studies | Synovium | Human primary LCLs (lymphoblastoid cell lines) | Not reported | Alarçin et al. 2020 [67] |
|
Triamcinolone acetonide | Dextran sulfate conjugated | Pre-clinical studies | Synovium | RAW 264.7 macrophages; L929 cells (mouse fibroblast) | Mice MIA model | She et al. 2020 [68] |
|
Hydrogels | Amphotericin B | Hyaluronic acid/glyceryl monooleate | Pre-clinical studies | Synovium, cartilage | Not reported | Rabbits | Shan-Bin et al. 2015 [69] |
Celecoxib | PCLA-PEG-PCLA | Pre-clinical studies | Synovium | Not reported | Horse | Petit et al. 2015 [34] |
|
Methotrexate/dexamethasone/near-infrared dye | Hyaluronic acid + PLGA microcapsules | Pre-clinical studies | Synovium | RAW 264.7 macrophages | Rat RA model | Son et al. 2015 [70] |
|
Sinomenine hydrochloride | Phytantriol | Formulation studies | Not reported | Not reported | Not reported | Chen et al. 2015 [71] |
|
Dexamethasone | Hyaluronic acid | Pre-clinical studies | Synovium, cartilage | Human primary chondrocytes | Rat ACLT model | Zhang et al. 2016 [72] |
|
PEGylated Kartogenin | Hyaluronic acid | Pre-clinical studies | Cartilage | Human BMSCs; human primary chondrocytes | Rat ACLT model | Kang et al. 2017 [73] |
|
Celecoxib | PCLA-PEG-PCLA | Pre-clinical studies | Synovium | Not reported | Equine synovitis model | Cokeleare et al. 2018 [74] |
|
Dexamethasone | Hyaluronic acid/pNiPAM | Pre-clinical studies | Synovium | Human synoviocytes | Mice DMM model | Maudens et al. 2018 [10] |
|
Triamcinolone hexacetonide (Cingal®) | Hyaluronic acid | Phase II/III clinical trials in OA patients | Synovium, cartilage | Not reported | Not reported | Hangody et al. 2018 [75] |
|
Simvastatin | Gelatin | Pre-clinical studies | Cartilage | Mouse primary chondrocytes | Mice | Tanaka et al. 2019 [76] |
|
Dexamethasone | Agarose gel + PLGA microspheres | Pre-clinical studies | Synovium, cartilage | 3D canine articular chondrocyte construct | Canine osteochondral autograft model | Stefani et al. 2020 [77] |
|
Diclofenac | Hyalomer (HA and poloxamer 407) | Pre-clinical studies | Synovium, cartilage | Not reported | Rat MIA model | Hanafy et al. 2020 [78] |
|
Diclofenac | Linked PAPE (2-Pyridylamino substituted 1-phenylethanol) | Formulation studies | Not reported | Not reported | Not reported | Kawanami et al. 2020 [79] |
|
Eicosapentanoic acid | Gelatin | Pre-clinical studies | Synovium | Human primary chondrocytes | Mouse DMM model | Tsubosaka et al. 2020 [80] |
|
Hyaluronic acid/diclofenac sodium | Silica colloidal crystal beads- pNiPAM | Pre-clinical studies | Synovium, cartilage | Human primary chondrocytes | Rat DMM model | Yang et al. 2020 [81] |
|
Liposomes | Quercetin | mPEG-PA (Methoxy-poly(ethylene glycol)-l-poly(alanine)) | Pre-clinical studies | Synovium, cartilage | Human primary chondrocytes | Rat ACLT model | Mok et al. 2020 [82] |
Fish oil protein encapsulated in gold nanoparticles | DPPC | Pre-clinical studies | Synovium | Not reported | Rats | Sarkar et al. 2019 [83] |
|
Glucosamine sulphate | Distearoyl phosphocholine |
Pre-clinical studies | Cartilage | Mouse primary chondrocytes | Not reported | Ji et al. 2019 [84] |
|
Rapamycin | DSPC combined with low-intensity pulsed ultrasound | Pre-clinical studies | Cartilage | Human primary chondrocytes | Guinea pigs | Chen et al. 2020 [85] |
Acronyms: PCL: polycaprolactone; PEA: polyetheramine; PLGA: poly(lactic-co-glycolic acid); PLA: polylactic acid; PVAL: poly(vinyl alcohol); PCLA: poly(ε-caprolactone-co-lactide); PEG: polyethylene glycol; pNiPAM: poly(N-isopropylacrylamide); PAMAM: poly(amidoamine); DPPC: dipalmitoylphosphatidylcholine; DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine; MIA: monoiodoacetate; AIA: antigen-induced arthritis; ACLT: anterior cruciate ligament transection; DMM: destabilization of medial meniscus.